Hematology

Latest News

Other AF prediction models have been proposed, including one with a machine-learning approach, but earlier models may not apply to patients taking second-generation BTKis. | Image Credit: sovova - stock.adobe.com

Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

By Jared Kaltwasser

May 15th 2025

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

One of the key ways to manage thromboembolic event risk in PV is by controlling hematocrit, often by prescribing hydroxyurea. If patients develop resistance to the therapy, however, they face a higher risk of mortality. | Image credit: keetazalay - stock.adobe.com

Machine Learning Model Identifies Hydroxyurea Resistance Markers in PV

By Jared Kaltwasser

May 6th 2025

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

By AJMC Contributor

May 1st 2025

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com

Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

By Rose McNulty

April 25th 2025

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

By Kyle Munz
Ajai Chari, MD

April 25th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

More News

A rituximab and lenalidomide combination (R-len) for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials | image credit: MQ-Illustrations - stock.adobe.com

February 18th 2025

Real-World Data Support Rituximab Plus Lenalidomide in NHL

A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.

Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com

February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

FDA approval | Image Credit: © wladimir1804 - stock.adobe.com

Published: February 12th 2025 | Updated: February 12th 2025

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).

Patient talking to doctor in appointment. | Image credit: Chinnapong – stock.adobe.com

February 10th 2025

Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers

Hayden E. Klein

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.

Mikkael Sekeres, MD

February 7th 2025

Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS

Rose McNulty Mikkael A. Sekeres, MD

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg

February 7th 2025

Refining Remission Assessment in Aggressive B-Cell Lymphomas

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.

cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com

February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

Mikkael Sekeres, MD

February 6th 2025

Treosulfan Shown Effective, Safe as Conditioning for Allo-HSCT in AML/MDS

Mikkael A. Sekeres, MD Rose McNulty

Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic stem cell transplantation (allo-HSCT).

Non-HodgkinLymphoma | Image Credit: © enterlinedesign-stock.adobe.com

January 30th 2025

SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

Extranodal NHL is not uncommon, comprising over 30% of NHL cases | image credit: Prostock Studio - stock.adobe.com

January 29th 2025

Study Expands Knowledge of Prognostic Markers in Extranodal NHL

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.

There remains a need for more diagnostic accuracy in cases of soft tissue NHL | image credit: phonlamaiphoto - stock.adobe.com

January 27th 2025

MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.

Kirollos Hanna, PharmD

January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

FDA approved. | Image Credit: Pawel - stock.adobe.com

January 23rd 2025

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com

January 21st 2025

High Infection Risk in MM: Insights From the Preimmunotherapy Era

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com

January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.

Man donating blood | Image Credit: © New Africa - stock.adobe.com

January 17th 2025

5 Medications That Defer Blood Donation

Experts stress that persons wanting to donate blood should not stop any medications they are on, with some deferrals being permanent and others temporary.

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com

January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Donating blood can save more than 1 life | image credit: Creative Cat Studio - stock.adobe.com

January 10th 2025

5 Things to Know About Donating Blood

Here are 5 things individuals should know about the powerful impact of blood donation and the benefits becoming a donor can have for patients in need.

mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com

January 9th 2025

Study Advocates Immunological Value of COVID-19 Vaccination in MM

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.

MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com

January 6th 2025

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

Kimberly Rath, PharmD

A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.

Among 55 evaluable samples analyzed, QPOP achieved an 87.3% success rate in generating individualized drug sensitivity reports. | Image credit: Eleni - stock.adobe.com

January 6th 2025

Functional Precision Medicine Tool Predicts Treatment Response in AML

Kimberly Rath, PharmD

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).

Don M. Benson, MD, PhD, James Cancer Hospital

January 2nd 2025

Honoring Patient Wishes in Myeloma Treatment Journeys

In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.

December 29th 2024

ICYMI: Highlights From ASH 2024

The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.

MM Top 5 Thumbnail

December 24th 2024

Top 5 Multiple Myeloma Content of 2024

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com

December 19th 2024

Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease

Karen Jacobson-Sive

Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Older patients with AML or MDS do not always receive the same care recommendations, a study found | image credit: Orawan - stock.adobe.com

December 19th 2024

Canadian Study Highlights Care Variability for Older Patients With MDS/AML

Kimberly Rath, PharmD

A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.

MDS graphic | Image Credit: © Sviatlana-stock.adobe.com

December 18th 2024

Luspatercept Promising Against Anemia in MDS

Kimberly Rath, PharmD

Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.

ICYMI: Highlights From IMS 2024

December 17th 2024

ICYMI: Highlights From IMS 2024

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.

MDS | Image Credit: © ibreakstock-stock.adobe.com

December 11th 2024

Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

Karen Jacobson-Sive

Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.

CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com

December 10th 2024

6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL

Jared Kaltwasser

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.

<1 2 3 4 5 6 7 8

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions